**

Overview


Crohn’s disease belongs to the family of inflammatory bowel diseases (IBD), a group of disorders characterized by persistent inflammation of the gastrointestinal (GI) tract. Unlike ulcerative colitis, which is limited to the colon and rectum, Crohn’s disease may involve any segment from the mouth to the anus, most commonly the terminal ileum and colon. The inflammation is transmural, meaning it penetrates the full thickness of the bowel wall, which predisposes patients to strictures, fistulas, and perforation. Typical symptoms include abdominal pain, persistent diarrhea, fever, abdominal distension, and unintended weight loss. Because the disease is systemic, many patients also experience fatigue, anemia, arthritis, eye inflammation (uveitis or episcleritis), and characteristic skin lesions such as erythema nodosum and pyoderma gangrenosum.

The course of Crohn’s disease is highly variable; some individuals have mild, intermittent flares, while others endure severe, progressive disease that necessitates surgery. Diagnosis relies on a combination of clinical assessment, laboratory tests (e.g., C‑reactive protein, fecal calprotectin), endoscopic evaluation with biopsies, and cross‑sectional imaging (CT or MR enterography). Treatment is multidisciplinary, aiming to induce remission, maintain symptom‑free intervals, and prevent complications. Therapeutic options include aminosalicylates, corticosteroids, immunomodulators (azathioprine, methotrexate), biologic agents targeting tumor necrosis factor‑α (TNF‑α) or integrins, and, when necessary, surgical resection of diseased segments.

Patients with Crohn’s disease should seek professional medical care promptly if they develop new or worsening abdominal pain, persistent high‑grade fever, signs of intestinal obstruction (vomiting, inability to pass gas or stool), or extra‑intestinal manifestations such as severe joint swelling or eye redness. Early intervention can reduce the risk of irreversible bowel damage and improve quality of life.

History/Background

The condition now known as Crohn’s disease was first described in a landmark 1932 paper by Burrill B. Crohn, Leon G. Ginzburg, and Egon S. Oppenheimer at Mount Sinai Hospital in New York. Their report detailed 14 patients with “regional ileitis,” distinguishing it from ulcerative colitis and other gastrointestinal disorders. The eponym “Crohn’s disease” gradually supplanted the original term, although the contributions of Ginzburg and Oppenheimer are increasingly recognized in modern histories.

Throughout the mid‑20th century, the disease was considered rare, but epidemiologic studies in the 1970s and 1980s revealed a rising incidence in industrialized nations, suggesting environmental and lifestyle influences. The discovery of genetic susceptibility loci—most notably the NOD2/CARD15 gene in the early 2000s—provided a molecular foothold for research. Subsequent genome‑wide association studies identified over 200 risk alleles, highlighting the complex interplay of genetics, the gut microbiome, and immune dysregulation.

Therapeutic milestones include the introduction of corticosteroids in the 1950s, the approval of azathioprine for maintenance therapy in the 1970s, and the revolutionary launch of infliximab, the first anti‑TNF biologic, in 1998. These advances transformed Crohn’s disease from a condition often requiring extensive surgery to one that can be medically managed for many patients.

Key Information

- Epidemiology: Affects 3–20 per 100,000 individuals worldwide; peak onset between ages 15–35; slight female predominance in some regions. - Pathophysiology: Multifactorial—genetic predisposition (e.g., NOD2, IL23R), abnormal immune response to intestinal microbiota, and environmental triggers (smoking, diet, antibiotics). - Clinical Features: Abdominal pain (often RLQ), non‑bloody diarrhea, weight loss, low‑grade fever, perianal disease (fistulas, abscesses). Extra‑intestinal: anemia, erythema nodosum, pyoderma gangrenosum, arthritis, uveitis, primary sclerosing cholangitis. - Complications: Bowel obstruction from strictures, fistula formation, malabsorption, nutritional deficiencies, increased risk of colorectal cancer (especially after 8–10 years of disease) and small‑bowel adenocarcinoma. - Diagnostic Tools: Colonoscopy with ileal intubation, capsule endoscopy, MR/CT enterography, serologic markers (ASCA, pANCA), fecal calprotectin. - Management: Induction of remission (corticosteroids, budesonide, biologics), maintenance (immunomodulators, anti‑TNF agents, anti‑integrins, ustekinumab), nutritional therapy (enteral formulas, exclusive liquid diets), and surgery (strictureplasty, resection) when medically refractory. - Monitoring: Regular colonoscopic surveillance beginning 8–10 years after diagnosis, especially for colonic involvement, to detect dysplasia early.

Significance

Crohn’s disease exemplifies the challenges of chronic immune‑mediated disorders: it imposes a lifelong burden on patients, families, and health‑care systems. The disease’s unpredictable flares and potential for serious complications demand coordinated care involving gastroenterologists, surgeons, nutritionists, rheumatologists, dermatologists, and mental‑health professionals. Advances in biologic therapy have dramatically improved remission rates and reduced the need for surgery, yet many patients still experience refractory disease, underscoring the need for novel targets and personalized medicine.

Beyond individual health, Crohn’s disease has spurred broader scientific insights into gut immunity, the microbiome, and the genetics of complex diseases. Research on Crohn’s has catalyzed the development of anti‑TNF agents now used across rheumatology, dermatology, and oncology. Public awareness and advocacy have also grown, leading to better insurance coverage for biologics and support for patient‑focused research. As the global incidence continues to rise, especially in newly industrialized nations, understanding and managing Crohn’s disease remains a public‑health priority.

INFOBOX:
- Name: Crohn’s disease (regional ileitis)
- Type: Chronic inflammatory bowel disease (IBD)
- Date: First described 1932
- Location: Can affect any part of the gastrointestinal tract (mouth to anus)
- Known For: Transmural inflammation, extra‑intestinal manifestations, and increased cancer risk

TAGS: inflammatory bowel disease, gastroenterology, autoimmune disease, chronic illness, biologic therapy, intestinal cancer, extra‑intestinal manifestations, patient education